Cytokinetics, Incorporated - Common Stock (CYTK)

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and

The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

B. Lynne Parshall sold $323,650 worth of Cytokinetics shares in November.

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Cytokinetics (CYTK) Q3 2025 Earnings Transcript

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.